



Investors & Analyst Communication on Financial Results

Q4 & year ended 31 March 2019

Dated:: 3 May 2019



Safe Harbour Statement

"This Presentation, except for the historical information, may contain statements, including the words or phrases such as 'expects, anticipates, intends, will, would, undertakes, aims, estimates, contemplates, seeks to, objective, goal, projects, should' and similar expressions or variations of these expressions or negatives of these terms indicating future performance or results, financial or otherwise of Tata Chemicals Limited, its direct and indirect subsidiaries and its associates. Actual results might differ substantially or materially from those expressed or implied. Important factors that could make a difference to the Company's operations include, among others, economic conditions affecting demand / supply, price conditions in the domestic and overseas markets in which the Company operates, changes in Government policies and regulations, tax laws, and other statutes and incidental factors. You are urged to view all statements contained herein with caution. Tata Chemicals Limited does not undertake any obligation to update or revise forward look statements, whether as a result of new information, future events or otherwise"



Key Highlights

- Highest sales volumes of Tata Salt
- Highest ever Operating Profit
- Consummated
 - Sale of Phosphatic Fertiliser Business in June 2018
 - Acquisition of Silica Business in June 2018
- Operating Working Capital at Standalone is all time low

Q4 FY19 Continuing Operations:

- Revenues: Consolidated Rs. 2,759 Cr (↑8%), Standalone Rs 1,059 Cr (↑ 15%)
- PAT: Consolidated Rs 450 Cr (↑ 26%), Standalone Rs 230 Cr (↑ 31%)

YTD FY19 Continuing Operations:

- Revenue : Consolidated Rs. 11,296 Cr (↑9%), Standalone Rs 4,081 Cr (↑ 16%)
- PAT : Consolidated Rs 1,395 Cr (↓ 11%), Standalone Rs 918 Cr (↑ 47%)

- Consolidated Net Debt position is at Rs 1,959 Cr, Cash & Cash Equivalent Rs 4,184 Cr
- Standalone Net Cash position is at Rs 2,521 Cr, Cash & Cash Equivalent Rs 3,229 Cr

The Company proposed dividend of Rs 12.5 per share (subject to approval of Shareholders at AGM)



Financial Performance: 3 months ended Mar19 (Q4 Mar - FY2019)






Financial Performance: 12 months ended Mar19 (YTD Mar - FY2019)









Financial Position: Balance Sheet

Do Cu	Consol	idated	Standalone			
Rs Cr	31-Mar-18	31-Mar-19	31-Mar-18	31-Mar-19		
ASSETS						
Non - Current Assets	16,839	18,807	8,484	9,528		
Current Assets						
Inventories	1,462	1,726	451	628		
Trade Receivables	1,308	1,453	140	185		
Cash and Cash Equivalent*	4,575	4,204	3,769	3,247		
Others Current Assets	597	717	244	410		
Assets Classified as held for Sale	1,098	-	1,086	-		
Total Assets	25,879	26,905	14,174	13,998		
EQUITY AND LIABILITIES						
Equity & Reserves	11,102	12,341	11,324	11,796		
Non - Controlling Interests	2,717	2,915	-	-		
Non-Current Liabilities						
Borrowings (Non Current)	5,394	4,783	681	13		
Non-Current Liabilities	2,962	2,917	300	304		
Current Liabilities						
Borrowings (Current)	140	352	1	1		
Trade Payables	1,479	1,475	425	569		
Others Current Liabilities	1,535	2,121	893	1,315		
Liabilities associated with assets	550		EEO			
classified as held for Sale	550	-	550	-		
Total Equities and Liabilities	25,879	26,905	14,174	13,998		

^{* 31} Mar 2019 Standalone Cash and Cash Equivalent Includes other bank balances & Liquid Investments




Financial Update: Borrowing position





Business Updates: Basic Chemistry Products

- India business continues to perform as per expectation. Revenues stood at Rs 853 Cr (up 25% vs PY), due to higher sales volumes in soda ash and Sodium bicarbonate and better sales realization, which was partly offset by higher power cost and plant fixed costs.
- TATA Chemicals North America business is on the path of recovery.
 Revenues stood at Rs 870 Cr (up by 6% vs PY), due to favorable sales realization, which was partly offset by lower sales volumes. Margins where impacted on account of higher distribution costs and other fixed cost.
- TATA Chemicals Europe business was under pressure due to lower sales volumes, partly off set by favorable sales realization. Revenues stood at Rs 381 Cr (up by 4% vs PY). Margins where suppressed due to higher energy cost and plant fixed costs.
- TATA Chemicals Magadi business continues to focus on improving operational efficiencies. Revenue stood at Rs 141 Cr (up 4% vs PY), due to higher sales realization. Margins were better due to lower fixed cost, which was partly off set by higher fuel cost.





Update on the Mithapur expansion Plan								
Products	Proposed Capacity Increase	Status						
Salt	400,000 MT							
Soda Ash	200,000 MT	Ongoing as						
Bicarb	35,000 MT	planned						
Cement	300,000 MT							



Business Updates: Consumer Products

- Salt Business continues to maintain its leadership position, with more than 25% market share in edible salt market and approximately 65% market share in branded salt market.
- Revenues from Pulses and Spices platform grew by more than 100 % during the period, with volumes doubling in both the category for the same period.
- Overall, Revenue from Consumer Products business stood at Rs 479 Cr (up 19% vs PY), mainly due to higher sales volume across category and controlled marketing investments during the period.
- During the period under review, we have launched 2 major products i.e.
 TATA Sampann Dal-icious snacks with 3 different flavors i.e. Tomato,
 Masala and Sasi Salsa. Currently, the product is under pilot launch in
 Pune, for which we have received good customer feedback.
- During the quarter, we also launched TATA Dx, detergent powder which
 is our foray into Home care / non food segment. TATA Dx is also in pilot
 stage in West Bengal. Initial responses for the products was very
 encouraging, with few customers being repeat customers.








Business Updates: Specialty Products

- Under Specialty products, Nutritional solutions business had a challenging quarter, as revenue where marginally impacted due to lower sales volumes. Margins where also impacted due to higher fixed costs primarily due to marketing overheads.
- Rallis India also had a challenging quarter, as revenue stood at Rs 340
 Cr (down 9% vs PY), on account of lower sales volumes and sales relisation. Margins where also impacted due to higher fixed cost and higher import prices of materials.

Updates on the new projects

- Nellore unit:
 - final stage of commissioning
 - Plan to have trial run during 3 quarter of FY20
 - Post statutory approval, expected to start commercial production as planned.
- Cuddalore unit (Allied Silica)
 - Completed initial trail run during the period.
 - Expect to start commercial production as scheduled.







Business Updates: Subsidiary Financials

	Q4 Mar – FY2019																
Units	TCL I	India		US		UK			Africa			Rallis			Consolidated*		
Rs Cr	PY	CY	P	Υ	CY		PY	CY		PY	CY		PY	CY		PY	CY
Revenue	918	1,059	8	319	870		368	381		136	141		371	340		2,555	2,759
EBITDA	257	266	1	L 41	205		79	27		21	31		35	7		512	531
PBT	271	283		68	234		28	(30)		11	23		25	6		372	479
PAT	175	230	1	L04	207		28	(15)		11	23		20	2		314	409

YT	DN	1ar –	FY2	019

	Units	TCL I	ndia		U	S	U	K	Afr	ica	Ra	llis	Consoli	dated*
	Rs Cr	PY	CY	P	γ	CY	PY	CY	PY	CY	PY	CY	PY	CY
	Revenue	3,524	4,081	3,2	257	3,382	1,436	1,449	481	506	1,809	1,984	10,345	11,296
Ì	EBITDA	922	1,002	6	688	678	218	105	82	59	265	241	2,191	2,095
	PBT	904	1,220	2	439	454	59	(53)	38	21	227	220	1,571	1,643
1	PAT	624	918	5	527	308	59	(38)	38	21	168	155	1,291	1,164


^{*} Include SPV and after consolidation adjustments


 $[\]hbox{-} \ {\tt PBT} \ is \ after \ exceptional \ items \ \& \ Share \ of \ profit \ of \ Joint \ Ventures \ and \ {\tt PAT} \ (after \ {\tt NCI}) \ for \ Equity \ Shareholders$



Key Products: Production & Sales









Awards, Recognitions and Customer connect









Customer Connect









Utsav Exhibition, Pune (Oct'18)







Other Financials Highlights













For any question/queries please contact

W.	lohn Mulhall	\boxtimes	jmulhal	l@tatachemical	ls.com (<u>a</u> +91	22 6665 8282
----	--------------	-------------	---------	----------------	----------	--------------	--------------

🏅 Sameer Kulkarni 🔻 sakulkarni@tatachemicals.com 🐚 +91 22 6665 7942

🎍 Gavin Desa 🖂 gavin@cdr-india.com 🐚 +91 22 6645 1237

Suraj Digawalekar

 Suraj@cdr-india.com

 ⊕ +91 22 6645 1235

Registered Office: Bombay House, 24 Homi Mody Street, Fort, Mumbai, Maharashtra 400 001 India.

Tel: (022) 6665 8282 Fax: (022) 6665 8143 / 44